Drug Guide
Moxifloxacin Hydrochloride
Classification
Therapeutic: Antibiotic / Antimicrobial
Pharmacological: Fluoroquinolone antibiotic
FDA Approved Indications
- Bacterial conjunctivitis (Vigamox, Moxeza)
- Community-acquired pneumonia
- Sinusitis
- Skin and skin structure infections
- Intra-abdominal infections
- Pseudo-membranous colitis
Mechanism of Action
inhibits bacterial DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication, transcription, repair, and recombination, leading to bacterial cell death.
Dosage and Administration
Adult: Typically 400 mg once daily for systemic infections; ophthalmic preparations (Vigamox, Moxeza) administered as per ophthalmic dose recommendations.
Pediatric: Use varies; consult specific product guidelines. Ophthalmic forms are approved for children over 1 year.
Geriatric: No specific dose adjustment required; monitor for adverse effects.
Renal Impairment: No dose adjustment necessary for most patients; however, caution is advised in severe renal impairment.
Hepatic Impairment: No specific adjustment recommended.
Pharmacokinetics
Absorption: Systemic absorption is rapid when given orally; ophthalmic formulations have minimal systemic absorption.
Distribution: Widely distributed in body tissues and fluids.
Metabolism: Partially metabolized; primarily excreted unchanged.
Excretion: Renal elimination; primarily unchanged drug in urine.
Half Life: Approximately 12 hours.
Contraindications
- Hypersensitivity to moxifloxacin or other fluoroquinolones.
Precautions
- Tendonitis and tendon rupture risk, especially in older adults and concurrent corticosteroid use.
- Central nervous system effects, including dizziness and confusion.
- Peripheral neuropathy.
- Seizures.
- Pregnancy and lactation: Use only if clearly needed; potential risks to fetus/infant.
Adverse Reactions - Common
- Nausea (Common)
- Headache (Common)
- Diarrhea (Common)
- Vaginal candidiasis (Common)
Adverse Reactions - Serious
- Tendon rupture (Rare)
- CNS effects (e.g., seizures, hallucinations) (Rare)
- QT prolongation and arrhythmias (Rare)
- Serious hypersensitivity reactions (Rare)
Drug-Drug Interactions
- Other drugs prolonging QT interval (e.g., amiodarone, sotalol).
- Theophylline (may increase serum levels).
- Anti-diabetic agents (may alter blood glucose levels).
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor for signs of tendonitis or tendon rupture, CNS effects, and hypersensitivity reactions. Assess renal function before systemic use.
Diagnoses:
- Risk for tendon injury
- Altered mental status
- Potential for hypersensitivity
Implementation: Administer as prescribed; inform patients about possible side effects; advise hydration to reduce crystalluria.
Evaluation: Monitor symptom resolution and adverse effect emergence.
Patient/Family Teaching
- Report any sudden tendon pain, swelling, or rupture.
- Be aware of neurological changes such as dizziness, confusion, or tremors.
- Avoid excessive sun exposure; photosensitivity can occur.
- Complete the full course of therapy even if symptoms improve.
Special Considerations
Black Box Warnings:
- Tendonitis and tendon rupture, peripheral neuropathy, CNS effects.
Genetic Factors: None specified.
Lab Test Interference: May cause false elevation in serum bilirubin levels.
Overdose Management
Signs/Symptoms: Nausea, vomiting, dizziness, neurological symptoms.
Treatment: Supportive care; no specific antidote. Dialysis may be considered in severe cases.
Storage and Handling
Storage: Store at controlled room temperature (20-25°C). Keep container tightly closed.
Stability: Stable for the duration of the labeled shelf life when stored properly.